Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
---|
04/24/2012 | US8163305 Targeted cross-linked nanoparticles and their use in vivo gene delivery |
04/24/2012 | US8163303 Nutritional composition for the treatment of pressure ulcers |
04/24/2012 | US8163296 Dimensional analysis of saccharide conjugates with GPC and SEC-MALS |
04/24/2012 | US8163288 S. aureus polypeptides and antibodies |
04/24/2012 | US8163281 Treatment of drug-related side effect and tissue damage by targeting the CD24-HMGB1-Siglec10 axis |
04/24/2012 | US8163278 Administering secretin based on chymotrypsin level; attention deficit disorder, hyperactivity, autism |
04/24/2012 | US8163277 Deliver platelet rich plasma, sodium bicarbonate, calcium gluconate, choline chloride buffers, thrombin, collagen, epinephrine releasate, via catheter; stent implants |
04/24/2012 | CA2671383C Dried composition |
04/24/2012 | CA2614171C Copolymers for suppression of autoimmune diseases, and methods of use |
04/24/2012 | CA2542834C Conjugates or co-administration of igf-1 receptor ligands with anti-cancer chemotherapeutic agents |
04/24/2012 | CA2517544C Clostridial neurotoxins for treating uterine disorders |
04/24/2012 | CA2499496C Synthesis and characterization of novel systems for guidance and vectorization of compounds having a therapeutic activity |
04/24/2012 | CA2485959C Polypeptide cleavage process |
04/24/2012 | CA2473469C Tolerogenic peptides from myelin basic protein |
04/24/2012 | CA2472190C Composition comprising at least an oxazolin for inhibiting langerhans cell migration, and uses thereof |
04/24/2012 | CA2466244C Methods and apparatus for production of a micro-organ |
04/24/2012 | CA2439570C In-situ gel formation of pectins |
04/24/2012 | CA2433582C Peptides having inhibiting activity on the production of nitric oxide |
04/24/2012 | CA2431557C Derivatives of streptogramins, their preparation and compositions containing them |
04/24/2012 | CA2425599C Fumaric acid amides |
04/24/2012 | CA2414609C Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them |
04/24/2012 | CA2408752C Delivery systems for treatment of vascular disease |
04/24/2012 | CA2339529C Isolated and purified human soluble guanylyl cyclase .alpha.1/.beta.1 (hsgc .alpha.1/.beta.1) |
04/24/2012 | CA2277141C Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this procedure |
04/19/2012 | WO2012051581A2 Intestinal peptide targeting ligands |
04/19/2012 | WO2012051567A2 Obesity-related genes and their proteins and uses thereof |
04/19/2012 | WO2012051556A1 Compositions and methods for the treatment of cardiac surgery-associated acute kidney injury with annexin a1 peptide |
04/19/2012 | WO2012051518A2 Compounds and methods for treating or preventing disease conditions associated with alpha-1-antitrypsin |
04/19/2012 | WO2012051459A1 Nucleic acid delivery compounds |
04/19/2012 | WO2012051458A1 Nucleic acid delivery compounds |
04/19/2012 | WO2012051457A1 Nucleic acid delivery compounds |
04/19/2012 | WO2012051447A1 Targeted delivery of targeted exocytosis modulators to the sphenopalatine ganglion for treatment of headache disorders |
04/19/2012 | WO2012051415A2 Inhibitors of acid ceramidase and uses thereof in cancer and other disease treatment therapies |
04/19/2012 | WO2012051247A2 Egfr-based peptides |
04/19/2012 | WO2012051106A1 Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate |
04/19/2012 | WO2012050978A1 Formulations of ubiquinol and resveratrol esters |
04/19/2012 | WO2012050930A2 Engineered polypeptides having enhanced duration of action |
04/19/2012 | WO2012050925A2 Highly soluble leptins |
04/19/2012 | WO2012050921A2 Nd2 peptides and methods of treating neurological disease |
04/19/2012 | WO2012050892A2 Methods for stimulating, increasing or enhancing killing of a cell that expresses luteinizing hormone releasing hormone (lhrh) receptors |
04/19/2012 | WO2012050850A1 Polycyclic heterocycle derivatives and methods of use thereof for the treatment of viral diseases |
04/19/2012 | WO2012050822A1 Uses of macrophage mannose receptor to screen compounds and uses of these compounds |
04/19/2012 | WO2012050714A2 Cartilage oligomeric matrix protein (comp)-growth factor complexes and uses thereof |
04/19/2012 | WO2012050695A1 Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients |
04/19/2012 | WO2012050673A1 Methods for the treatment of x-linked hypophosphatemia and related disorders |
04/19/2012 | WO2012050611A2 Aptamers to glycoprotein vi |
04/19/2012 | WO2012050402A2 Cell-permeable recombinant parkin protein and a pharmaceutical composition for treating degenerative brain diseases containing the same |
04/19/2012 | WO2012050374A2 Immunotherapy for solid tumors |
04/19/2012 | WO2012050303A2 Pharmaceutical composition for cancer prevention and treatment containing the c12orf59 gene or protein as an active ingredient |
04/19/2012 | WO2012050193A1 Ebola virus liposome vaccine |
04/19/2012 | WO2012050184A1 Sustained-release pharmaceutical composition |
04/19/2012 | WO2012049636A1 Eif6 phosphorylation antagonists for use in medicine |
04/19/2012 | WO2012049430A2 Hydrolysates of animal proteins of marine origin with neuroprotective properties |
04/19/2012 | WO2012049332A1 Peptides and uses |
04/19/2012 | WO2012049324A2 New emd formulation comprising pga |
04/19/2012 | WO2012049312A1 Suppression of a type 1 hypersensitivity immune response with an unrelated antigen |
04/19/2012 | WO2012049310A1 Suppression of a hypersensitivity immune response with unrelated antigen derived from allergen source material |
04/19/2012 | WO2012049245A1 Method for purification of complement factor h |
04/19/2012 | WO2012049215A1 Antimicrobial protein |
04/19/2012 | WO2012048893A1 Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases |
04/19/2012 | WO2012048721A1 Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases |
04/19/2012 | WO2012048667A1 Epidermal growth factor receptor variant lacking exon |
04/19/2012 | WO2012048653A1 Long-life interferon fusion protein and use thereof |
04/19/2012 | WO2012021796A3 Novel cyclosporin derivatives for the treatment and prevention of a viral infection |
04/19/2012 | WO2012015692A3 Recombinantly expressed insulin polypeptides and uses thereof |
04/19/2012 | WO2012013742A3 Stabilization of fsh |
04/19/2012 | WO2012006329A3 Apoe4 and apoj biomarker-based prevention and treatment of dementia |
04/19/2012 | WO2012004416A3 Treatment of a disease associated with retinal degenerative disorder |
04/19/2012 | WO2012003516A3 Preservative-free follicle stimulating hormone solution delivery device |
04/19/2012 | WO2012003452A3 Perlecan domain v protects, repairs and restores ischemic brain stroke injury and motor function |
04/19/2012 | WO2011163669A3 Co-delivery of stimulatory and inhibitory factors to create temporally stable and spatially restricted zones |
04/19/2012 | WO2011163646A3 Methods for detection, diagnosis and selective eradication of neoplasms and circulating tumor cells using multidomain biotags |
04/19/2012 | WO2011163637A3 Protein transduction domains mimics |
04/19/2012 | WO2011163394A9 Compstatin analogs for treatment of neuropathic pain |
04/19/2012 | WO2011163312A3 Improving efficacy of cancer therapy |
04/19/2012 | WO2011163308A3 Compositions and methods for preventing and treating organ injury and/or dysfunction |
04/19/2012 | WO2011159970A3 Method for predicting a therapy response in subjects with multiple sclerosis |
04/19/2012 | WO2011159771A3 Compositions and methods for treating cancer |
04/19/2012 | WO2011156774A3 Multivalent glycopeptide constructs and uses thereof |
04/19/2012 | WO2011156736A3 Targeted mucosal treatment of obesity and diabetes |
04/19/2012 | WO2011156453A3 Therapeutic peptides |
04/19/2012 | WO2011155727A3 Method for preventing and treating infection caused by salmonella choleraesuis or salmonella dublin |
04/19/2012 | WO2011153525A9 Methods for treatment of nephrotic syndrome and related conditions |
04/19/2012 | WO2011153512A3 Use of compounds with thrombopoietic activity to promote bone growth and healing |
04/19/2012 | WO2011153491A3 Agonists of growth hormone releasing hormone as effectors for survival and proliferation of pancreatic islets |
04/19/2012 | WO2011152662A9 Ptd-uqcrb fusion polypeptide, and pharmaceutical composition for preventing and treating ischemic diseases, containing same |
04/19/2012 | WO2011150418A3 Compositions and methods for treating pathologies |
04/19/2012 | WO2011150127A3 Novel systems, vectors, and methods for delivery of biomolecules to eukaryotic cells |
04/19/2012 | WO2011150094A3 Tumor suppression compositions |
04/19/2012 | WO2011149310A3 Peptide for inhibiting interaction between rankl and rank, and pharmaceutical composition containing same |
04/19/2012 | WO2011146922A3 Materials and methods for treatment of inflammation |
04/19/2012 | WO2011146518A9 Pegylated c-peptide |
04/19/2012 | WO2011144674A3 PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND SBE4-ß-CYD |
04/19/2012 | WO2011133566A3 Repairing bruch's membrane with hydrogels |
04/19/2012 | WO2011130618A3 Compositions and methods for producing glycosylated human pdx-1 protein and methods of use therefore |
04/19/2012 | WO2011127393A3 Variants of ancestral uricases and uses thereof |
04/19/2012 | WO2011127202A3 Methods for identifying and using inhibitors of casein kinase 1 epsilon isoform for inhibiting the growth and/or proliferation of myc-driven tumor cells |
04/19/2012 | WO2011126864A3 Cancer treatment with recombinant vector |
04/19/2012 | WO2011123826A3 Prevention and treatment of cast nephropathy |
04/19/2012 | WO2011122916A3 Composition for increasing trail sensitivity, containing an inhibitor for inhibiting the expression or activity of tip41 which is a trail sensitizer target gene |